

IN THE CLAIMS

Please revise Claims 1-51 and adds new Claims 52-74, as follows:

1. **(Currently Amended)** A combination comprising a first amount of an aldosterone receptor antagonist and a second amount of a beta-adrenergic antagonist, wherein said aldosterone receptor antagonist and beta-adrenergic antagonist together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said beta-adrenergic antagonist, and

wherein said aldosterone receptor antagonist is selected from the group consisting of eplerenone and spironolactone, and

wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, viskenit, Acc 9369, AMO-140, betaxolol, capsinolol, carazolol, CP-331684, diprafenone, ersentilide, esmolol, esprolol, Fr-172516, ISV-208, L-653328, laniolol, levobunolol, LM-2616, nipradilol, Pharmaprojects No 5279, S-atenolol, SB-226552, SR-58894A, SR-59230A. talinolol, tertatolol, tilisolol, TZC-5665, UK-1745, xamoterol, and YM-430.

2. **(Cancelled)**

3. **(Cancelled)**

4. (Cancelled)

5. (Cancelled)

6. (Currently Amended) The combination of Claim 4 1 wherein said ~~epoxy-steroidal-type compound~~ aldosterone receptor antagonist is eplerenone.

7. (Original) The combination of Claim 6 wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, and viskenit.

8. (Original) The combination of Claim 6 wherein said beta-adrenergic antagonist is selected from the group consisting of Acc 9369, AMO-140, betaxolol, capsinolol, carazolol, CP-331684, diprafenone, ersentilide, esmolol, esprolol, Fr-172516, ISV-208, L-653328, laniolol, levobunolol, LM-2616, nipradilol, Pharmaprojects No 5279, S-atenolol, SB-226552, SR-58894A, SR-59230A, talinolol, tertatolol, tilisolol, TZC-5665, UK-1745, xamoterol, and YM-430.

9. (Original) The combination of Claim 7 further characterized by said beta-adrenergic antagonist and said epoxy-steroidal aldosterone receptor antagonist being present in said combination in a weight ratio range from about one-to-one to about one-to-twenty of said beta-adrenergic antagonist to said aldosterone receptor antagonist.

10. (Original) The combination of Claim 9 wherein said weight ratio range is from about one-to-five to about one-to-fifteen.

11. **(Original)** The combination of Claim 10 wherein said weight ratio range is about one-to-ten.

12. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises carvedilol or a pharmaceutically-acceptable salt thereof.

13. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises metoprolol or a pharmaceutically-acceptable salt thereof.

14. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises bisoprolol or a pharmaceutically-acceptable salt thereof.

15. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises bucindolol or a pharmaceutically-acceptable salt thereof.

16. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises propranolol or a pharmaceutically-acceptable salt thereof.

17. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises esmolol or a pharmaceutically-acceptable salt thereof.

18. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises acebutolol or a pharmaceutically-acceptable salt thereof.

19. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises sotalol or a pharmaceutically-acceptable salt thereof.

20. **(Original)** The combination of Claim 6 wherein the beta-adrenergic antagonist comprises labetalol or a pharmaceutically-acceptable salt thereof.

21. **(Currently Amended)** The combination of Claim 1 wherein said aldosterone receptor antagonist is spironolactone.

22. **(Original)** The combination of Claim 21 wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, and viskenit.

23. **(Original)** The combination of Claim 21 wherein said beta-adrenergic antagonist is selected from the group consisting of Acc 9369, AMO-140, betaxolol, capsinolol, carazolol, CP-331684, diprafenone, ersentilide, esmolol, esprolol, Fr-172516, ISV-208, L-653328, laniolol, levobunolol, LM-2616, nipradilol, Pharmaprojects No 5279, S-atenolol, SB-226552, SR-58894A, SR-59230A, talinolol, tertatolol, tilisolol, TZC-5665, UK-1745, xamoterol, and YM-430.

24. **(Original)** The combination of Claim 22 further characterized by said beta-adrenergic antagonist and said aldosterone receptor antagonist being present in said combination in a weight ratio range from about one-to-one to about one-to-twenty of said beta-adrenergic antagonist to said aldosterone receptor antagonist.

25. **(Original)** The combination of Claim 24 wherein said weight ratio range is from about one-to-five to about one-to-fifteen.

26. **(Original)** The combination of Claim 25 wherein said weight ratio range is about one-to-ten.

27. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises carvedilol or a pharmaceutically-acceptable salt thereof.

28. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises metoprolol or a pharmaceutically-acceptable salt thereof.

29. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises bisoprolol or a pharmaceutically-acceptable salt thereof.

30. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises bucindolol or a pharmaceutically-acceptable salt thereof.

31. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises propranolol or a pharmaceutically-acceptable salt thereof.

32. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises esmolol or a pharmaceutically-acceptable salt thereof.

33. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises acebutolol or a pharmaceutically-acceptable salt thereof.

34. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises sotalol or a pharmaceutically-acceptable salt thereof.

35. **(Original)** The combination of Claim 21 wherein the beta-adrenergic antagonist comprises labetalol or a pharmaceutically-acceptable salt thereof.

36. **(Cancelled)**

37. **(Cancelled)**

38. **(Cancelled)**

39. **(Cancelled)**

40. **(Cancelled)**

41. **(Cancelled)**

42. **(Currently Amended)** A pharmaceutical composition comprising a first amount of an aldosterone receptor antagonist, and a second amount of a beta-adrenergic antagonist and a pharmaceutically acceptable carrier, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said beta-adrenergic antagonist, and

wherein said aldosterone receptor antagonist and beta-adrenergic antagonist together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said beta-adrenergic antagonist is selected from the group consisting of eplerenone and spironolactone, and

wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, viskenit, Acc 9369, AMO-

140, betaxolol, capsinolol, carazolol, CP-331684, diprafenone, ersentilide, esmolol, esprolol, Fr-172516, ISV-208, L-653328, laniolol, levobunolol, LM-2616, nipradilol, Pharmaprojects No 5279, S-atenolol, SB-226552, SR-58894A, SR-59230A. talinolol, tertatolol, tilisolol, TZC-5665, UK-1745, xamoterol, and YM-430.

43. (Cancelled)

44. (Cancelled)

45. (Cancelled)

46. (Currently Amended) The pharmaceutical composition of Claim 45 42 wherein said aldosterone receptor antagonist epoxy-steroidal-type compound is eplerenone.

47. (Original) The pharmaceutical composition of Claim 42 wherein said aldosterone receptor antagonist is spironolactone.

48. (Currently Amended) A therapeutic method for treating a cardiovascular disorder, said method comprising administering to a subject susceptible to or afflicted with such disorder a first amount of an aldosterone receptor antagonist and a second amount of a beta-adrenergic antagonist,

wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said beta-adrenergic antagonist, and

wherein said aldosterone receptor antagonist and beta-adrenergic antagonist together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said beta-adrenergic antagonist is selected from the group consisting of eplerenone and spironolactone, and said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol,

bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol,
bunitrolol, butofilolol, carteolol, carvedilol, celiprolol,
cloranolol, indenolol, labetalol, levoprolol, mepindolol,
metipranolol, metoprolol, nadolol, nebivolol, nifenalol,
oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol,
toprol, viskenit, Acc 9369, AMO-140, betaxolol, capsinolol,
carazolol, CP-331684, diprafenone, ersentilide, esmolol,
esprolol, Fr-172516, ISV-208, L-653328, laniolol, levobunolol,
LM-2616, nipradilol, Pharmaprojects No 5279, S-atenolol, SB-
226552, SR-58894A, SR-59230A. talinolol, tertatolol, tilisolol,
TZC-5665, UK-1745, xamoterol, and YM-430.

49. **(Original)** The method of Claim 48, wherein said cardiovascular disorder is selected from the group consisting of hypertension, congestive heart failure, cirrhosis and ascites.

50. **(Original)** The method of Claim 49, wherein said cardiovascular disorder is hypertension.

51. **(Original)** The method of Claim 49, wherein said cardiovascular disorder is congestive heart failure.

52. **(NEW)** The pharmaceutical composition of Claim 46 wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, and viskenit.

53. **(NEW)** The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises carvedilol or a pharmaceutically-acceptable salt thereof.

54. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises metoprolol or a pharmaceutically-acceptable salt thereof.

55. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises bisoprolol or a pharmaceutically-acceptable salt thereof.

56. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises bucindolol or a pharmaceutically-acceptable salt thereof.

57. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises propranolol or a pharmaceutically-acceptable salt thereof.

58. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises esmolol or a pharmaceutically-acceptable salt thereof.

59. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises acebutolol or a pharmaceutically-acceptable salt thereof.

60. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises sotalol or a pharmaceutically-acceptable salt thereof.

61. (NEW) The pharmaceutical composition of Claim 46 wherein the beta-adrenergic antagonist comprises labetalol or a pharmaceutically-acceptable salt thereof.

62. (NEW) The pharmaceutical composition of Claim 47 wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol,

labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, and viskenit.

63. (NEW) The method of Claim 48 wherein said aldosterone receptor antagonist and said beta-adrenergic antagonist are administered in a sequential manner.

64. (NEW) The method of Claim 48 wherein said aldosterone receptor antagonist and said beta-adrenergic antagonist are administered in a substantially simultaneous manner.

65. (NEW) The method of Claim 48 wherein said aldosterone receptor antagonist is eplerenone.

66. (NEW) The method of Claim 65 wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, and viskenit.

67. (NEW) The method of Claim 65, wherein said cardiovascular disorder is selected from the group consisting of hypertension, congestive heart failure, cirrhosis and ascites.

68. (NEW) The method of Claim 67, wherein said cardiovascular disorder is hypertension.

69. (NEW) The method of Claim 67, wherein said cardiovascular disorder is congestive heart failure.

70. (NEW) The method of Claim 48 wherein said aldosterone receptor antagonist is spironolactone.

71. **(NEW)** The method of Claim 70 wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, cloranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, and viskenit.

72. **(NEW)** The method of Claim 70, wherein said cardiovascular disorder is selected from the group consisting of hypertension, congestive heart failure, cirrhosis and ascites.

73. **(NEW)** The method of Claim 72, wherein said cardiovascular disorder is hypertension.

74. **(NEW)** The method of Claim 72, wherein said cardiovascular disorder is congestive heart failure.